Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial

BACKGROUND: The Phase 3 CT-P6 3.2 study demonstrated equivalent efficacy and comparable safety between CT-P6 and reference trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer after up to 3 years’ follow-up. OBJECTIVE: To investigate long-term sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Stebbing, Justin, Baranau, Yauheni, Baryash, Valery, Moiseyenko, Vladimir, Boliukh, Dmytro, Antone, Nicoleta, Manikhas, Alexey, Chornobai, Anatolii, Park, Taehong, Baek, Eric Hyungseok, Lee, Jaeyong, Choi, Jiin, Kim, Nahyun, Ahn, Keumyoung, Lee, Sang Joon, Kim, Sunghyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195725/
https://www.ncbi.nlm.nih.gov/pubmed/36881323
http://dx.doi.org/10.1007/s40259-023-00582-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195725/
https://www.ncbi.nlm.nih.gov/pubmed/36881323
http://dx.doi.org/10.1007/s40259-023-00582-w

Ejemplares similares